Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02546739Phase 1Unknown

Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL

Role: lead

NCT03271515Phase 1Unknown

Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

Role: lead

NCT02585908Phase 1Unknown

Safety and Efficacy of γδ T Cell Against Gastric Cancer

Role: lead

NCT02602249Phase 1Unknown

Clinical Safety and Preliminary Efficacy of MUC1-DC-CTL Treatment in Stage IV Gastric Cancer.

Role: lead

NCT02656147Phase 1Unknown

Immunotherapy With CD19 CAR γδT-cells for B-Cell Lymphoma, ALL and CLL

Role: lead

All 5 trials loaded